Albion Venture Capital Trusts close £90M top-up offer as demand for UK innovation investments grows

Albion VCTs Hit £90 Million Milestone: A Game-Changer for UK DeepTech and Healthcare Innovation

In a landmark move for UK venture capital, the three Albion Venture Capital Trusts (VCTs) have successfully closed their £90 million top-up fundraising campaign, hitting their hard cap and going oversubscribed. This achievement underscores the growing appetite among investors for tax-efficient exposure to Britain’s most ambitious early-stage companies—particularly in high-growth sectors like deeptech, healthcare, and B2B software.

For those unfamiliar, VCTs are publicly listed investment vehicles that allow individuals to back unlisted, high-potential companies while enjoying generous tax reliefs—including 30% upfront income tax relief, tax-free dividends, and no capital gains tax on share disposals. Albion’s VCTs, managed by Albion Capital, have been a dominant force in this space, raising over £405 million in the past five years alone.

What makes this latest £90 million raise particularly compelling is not just the size, but the momentum behind it. Over the last three years, 64% of companies in Albion’s VCT portfolio have progressed from the growth stage to scale-up—a strong indicator of both the quality of the fund’s deal flow and its ability to nurture startups through critical inflection points.

The capital will be strategically deployed into Albion’s core conviction sectors. Deeptech remains a focal point, with investments in companies pushing the boundaries of artificial intelligence, quantum computing, and advanced materials. Healthcare is another priority, especially digital health platforms that are transforming patient outcomes at scale. And in B2B software, Albion is backing SaaS innovators solving complex enterprise challenges.

Among the standout portfolio companies is Quantexa, a global leader in decision intelligence that uses AI to help organizations make sense of complex data. The company recently hit unicorn status and continues to expand its footprint across financial services and government sectors. Then there’s Oviva, Europe’s leading digital health company for weight management, which recently closed a £200 million Series D round, cementing its position as a scale-up to watch. And tem (The Energy Management Company), an AI-powered platform helping businesses slash energy costs through intelligent infrastructure, rounds out a portfolio that blends impact with profitability.

The deeptech and fintech ecosystems are also seeing significant activity. Gravity, a next-gen deeptech innovator, and TransFICC, a London-based trading technology platform that simplifies fixed-income electronic trading via a single API, have both secured substantial growth rounds—further validating Albion’s thesis on the convergence of technology and traditional industries.

Will Fraser-Allen, Managing Partner at Albion, framed the success of the fundraising as a broader endorsement of the VCT model: “Reaching our £90 million hard cap, oversubscribed, reflects the growing recognition investors have that VCTs are one of the most effective ways to back the next generation of UK entrepreneurs, while targeting long-term, tax-efficient returns.”

He added: “In an environment where tax efficiency and long-term growth are paramount, VCTs continue to offer a compelling proposition for those looking to back British breakthroughs. With a strong pipeline of investment opportunities across our core sectors, we are well-positioned to deploy this capital into companies driving technological and scientific progress, supporting ambitious founders in sectors where the UK is a global leader, while creating value for our shareholders and the wider economy alike.”

This latest raise comes at a pivotal moment for UK innovation. With global competition for deep tech and life sciences talent intensifying, and public markets remaining volatile, private capital—especially via tax-advantaged structures like VCTs—offers a unique lever for scaling homegrown breakthroughs. Albion’s ability to attract significant oversubscription also signals strong investor confidence in the UK’s startup ecosystem, despite macroeconomic headwinds.

For retail investors, the appeal is clear: access to a diversified portfolio of high-growth companies, many of which are at the cutting edge of AI, healthcare, and enterprise software, with the added benefit of tax efficiency. For founders, it means more capital is available to fuel the next wave of UK scale-ups—companies that could one day rival the likes of DeepMind, Arm, or BenevolentAI.

As the £90 million begins to flow into new and existing portfolio companies, all eyes will be on Albion’s deal-making in the coming months. If the past is any guide, this capital could help birth the next generation of UK unicorns—companies that not only deliver outsized returns but also solve some of society’s most pressing challenges.

Tags: Albion VCTs, Venture Capital Trusts, UK startups, deeptech investment, healthcare innovation, B2B software, Quantexa, Oviva, tem, Gravity, TransFICC, tax-efficient investing, scale-up growth, AI startups, digital health, energy management, UK innovation, venture capital, startup funding, high-growth companies, Albion Capital, investment opportunities, fintech, deep tech, portfolio companies, founders, technological progress, scientific breakthroughs, British entrepreneurs, tax relief, income tax relief, capital gains tax, public markets, macroeconomic headwinds, retail investors, diversified portfolio, next-gen unicorns, DeepMind, Arm, BenevolentAI, UK economy, shareholder value, investment vehicles, unlisted companies, Series D funding, AI-powered infrastructure, decision intelligence, weight management, fixed-income trading, single API, enterprise software, SaaS innovators, advanced materials, quantum computing, UK scale-ups, homegrown breakthroughs, investor confidence, deal flow, inflection points, public markets volatility, private capital, tax-advantaged structures, retail investors, cutting-edge technology, societal challenges, outsized returns, deal-making, next generation, UK entrepreneurs, long-term growth, tax efficiency, British breakthroughs, technological and scientific progress, ambitious founders, global competition, life sciences, talent, public markets, macroeconomic headwinds, diversified portfolio, high-growth companies, Quantexa, Oviva, tem, Gravity, TransFICC, tax-efficient investing, scale-up growth, AI startups, digital health, energy management, UK innovation, venture capital, startup funding, Albion Capital, investment opportunities, fintech, deep tech, portfolio companies, founders, technological progress, scientific breakthroughs, British entrepreneurs, tax relief, income tax relief, capital gains tax, public markets, macroeconomic headwinds, retail investors, diversified portfolio, next-gen unicorns, DeepMind, Arm, BenevolentAI, UK economy, shareholder value, investment vehicles, unlisted companies, Series D funding, AI-powered infrastructure, decision intelligence, weight management, fixed-income trading, single API, enterprise software, SaaS innovators, advanced materials, quantum computing, UK scale-ups, homegrown breakthroughs, investor confidence, deal flow, inflection points, public markets volatility, private capital, tax-advantaged structures, retail investors, cutting-edge technology, societal challenges, outsized returns, deal-making, next generation, UK entrepreneurs, long-term growth, tax efficiency, British breakthroughs, technological and scientific progress, ambitious founders, global competition, life sciences, talent, public markets, macroeconomic headwinds.

,